Skip to main content
SpringerLink
Log in

NICE's value assessments may restrict patient access

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Centralized government value assessments by UK NICE create barriers to patient access, particularly for cancer patients, new research shows. Internet Document : 21 Jul 2014. Available from: URL: http://www.phrma.org/sites/default/files/pdf/fact-sheet-nice-restrictiveness.pdf

  2. Pharmaceutical Research and Manufacturers of America. UK Cancer Patients Face Increasing Coverage Restrictions Due to Centralized Cost-Effectiveness Standard, New Report Shows. Media Release : 10 Jul 2014. Available from: URL: http://www.phrma.org

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE's value assessments may restrict patient access. PharmacoEcon Outcomes News 708, 2 (2014). https://doi.org/10.1007/s40274-014-1410-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1410-1

Search

Navigation